SEC Form 4 · accession 0001628280-26-060499
NEOGENOMICS INC · NEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alicia C Olivo
Officer — EVP, GC & Business Development
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 5:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001077183
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 1, 2026 | F | 2,692 | $0.00 | D | 90,875 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $19.12 | holding | — | — | — | — | Sep 30, 2026 | Common Stock | 1,046 | 1,046 | D |
| Stock Option (Right to Buy)F3 | $27.34 | holding | — | — | — | — | May 1, 2027 | Common Stock | 1,024 | 1,024 | D |
| Stock Option (Right to Buy)F4 | $48.99 | holding | — | — | — | — | May 1, 2028 | Common Stock | 516 | 516 | D |
| Stock Option (Right to Buy)F5 | $46.10 | holding | — | — | — | — | Aug 1, 2028 | Common Stock | 1,117 | 1,117 | D |
| Stock Option (Right to Buy)F6 | $9.45 | holding | — | — | — | — | May 1, 2029 | Common Stock | 22,222 | 22,222 | D |
| Stock Option (Right to Buy)F7 | $10.05 | holding | — | — | — | — | Sep 1, 2029 | Common Stock | 46,355 | 46,355 | D |
| Stock Option (Right to Buy)F8 | $19.65 | holding | — | — | — | — | May 11, 2030 | Common Stock | 36,508 | 36,508 | D |
| Restricted Stock UnitF9,F10 | $0.00 | holding | — | — | — | — | — | Common Stock | 2,559 | 2,559 | D |
| Performance Stock UnitF11,F10 | $0.00 | holding | — | — | — | May 11, 2026 | — | Common Stock | 19,508 | 19,508 | D |
| Stock Option (Right to Buy)F12 | $16.45 | holding | — | — | — | — | Feb 23, 2034 | Common Stock | 42,344 | 42,344 | D |
| Performance Stock UnitF13,F10 | $0.00 | holding | — | — | — | Feb 23, 2027 | — | Common Stock | 25,330 | 25,330 | D |
| Restricted Stock UnitF14,F10 | $0.00 | holding | — | — | — | — | — | Common Stock | 8,443 | 8,443 | D |
| Restricted Stock UnitF10 | $0.00 | holding | — | — | — | Jan 13, 2026 | — | Common Stock | 59,382 | 59,382 | D |
| Stock Option (Right to Buy)F15,F16 | $13.05 | holding | — | — | — | — | Feb 21, 2035 | Common Stock | 107,450 | 107,450 | D |
| Restricted Stock UnitF17,F10 | $0.00 | holding | — | — | — | — | — | Common Stock | 42,159 | 42,159 | D |
| Stock Option (Right to Buy)F18,F19 | $10.81 | holding | — | — | — | — | Mar 1, 2036 | Common Stock | 147,804 | 147,804 | D |
| Restricted Stock UnitF20,F10 | $0.00 | holding | — | — | — | — | — | Common Stock | 89,013 | 89,013 | D |
Explanation of responses
- F1Shares surrendered to NeoGenomics, Inc. for retirement to satisfy tax obligations in connection with the September 1, 2026 vesting of restricted stock.
- F10Once vested, the shares of common stock are not subject to expiration.
- F11On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
- F12On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- F13On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
- F14On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- F15This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
- F16On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- F17On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- F18This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%.
- F19On March 1, 2026, Ms. Olivo was granted 147,804 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- F2On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F20On March 1, 2026, Ms. Olivo was granted 89,013 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- F3On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F4On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F5On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F6On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F7On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F8On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- F9On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.